Sunday, 23 January 2022

Australia's most trusted
source of pharma news

Sunday, 23 January 2022

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (9)

Sales & Customer Relations (26)

Access & Reimbursement (1)

Clinical & Medical, R&D (17)

Regulatory, Pharmacovigilance & QA (6)

Other (16)


Department says 'sorry'

Posted 24 November 2021 AM

The Department of Industry, Science, Energy and Resources says it "sincerely apologises" to Noxopharm, which is currently weighing up taking legal action after it was incorrectly notified that it was a recipient of one of the largest Australian Government grants ever awarded to a biotech for a single drug program.

A spokesperson from the Department confirmed that the Sydney-based pharma was notified early November that it was the recipient of a $8.79 million grant for a sarcoma trial investigating its chemo-enhancing drug Veyonda.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.